10-Q: Assertio Holdings Reports Q3 2024 Results: Revenue Declines Amidst Generic Competition, ROLVEDON Sales Show Growth

Assertio Holdings experienced a decrease in overall revenue for the third quarter of 2024, primarily due to generic competition impacting legacy products, while ROLVEDON sales showed growth.

Summary

• Assertio Holdings reported a net loss of $2.9 million for the third quarter of 2024, compared to a significant loss of $279.5 million in the same period last year.
• Total revenue for Q3 2024 was $29.2 million, down from $35.6 million in Q3 2023.
• Product sales decreased to $28.7 million from $35.1 million year-over-year, with ROLVEDON sales increasing to $15.0 million, but INDOCIN sales declining to $5.7 million.
• The company's operating loss was $3.0 million for Q3 2024, a significant improvement from the $228.3 million loss in Q3 2023, which included a large impairment charge.
• For the nine months ended September 30, 2024, the net loss was $11.1 million, compared to a net loss of $274.6 million for the same period in 2023.
• Total revenue for the first nine months of 2024 was $92.8 million, down from $119.1 million in the same period of 2023.
• The company's cash and cash equivalents decreased to $38.0 million as of September 30, 2024, from $73.4 million at the end of 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's improvement in net loss and operating loss, revenue is down, and the company faces significant challenges from generic competition and legal issues. The decrease in cash is also concerning. The sentiment is cautiously negative.

Positives

• ROLVEDON sales are showing strong growth, reaching $15.0 million in Q3 2024, indicating successful integration of the Spectrum acquisition.
• The company's net loss significantly improved year-over-year, from a $279.5 million loss in Q3 2023 to a $2.9 million loss in Q3 2024.
• Operating loss improved substantially, from a $228.3 million loss in Q3 2023 to a $3.0 million loss in Q3 2024.
• The company is actively managing its cost structure, as evidenced by the decrease in selling, general, and administrative expenses.

Negatives

• Total revenue decreased to $29.2 million in Q3 2024, down from $35.6 million in Q3 2023.
• INDOCIN sales experienced a significant decline to $5.7 million in Q3 2024, down from $17.9 million in Q3 2023, due to generic competition.
• Otrexup, SPRIX, and CAMBIA also experienced sales declines in Q3 2024 compared to Q3 2023.
• Cash and cash equivalents decreased to $38.0 million as of September 30, 2024, from $73.4 million at the end of 2023.

Risks

• The company faces increasing generic competition for its products, particularly INDOCIN, which is expected to continue impacting sales.
• The company's reliance on single-source suppliers poses a risk to its supply chain.
• The company is involved in various legal proceedings, including opioid-related litigation and a qui tam lawsuit, which could result in significant costs and liabilities.
• The company's stock price has been trading below or slightly above $1.00 per share, which could lead to delisting from the Nasdaq Capital Market if not addressed.
• The company's future performance is subject to various risks, including the success of its commercialization efforts, the outcome of litigation, and the ability to manage its debt.

Future Outlook

The company expects that the average selling price for ROLVEDON will continue to be negatively impacted for the remainder of 2024 due to higher discounts, chargebacks, and rebates given to customers. INDOCIN net product sales are expected to continue to be impacted unfavorably by increasing competition. The company believes that its existing cash and cash equivalents and short-term investments will be sufficient to fund its operations and make the required payments under its debt agreements due for at least the next twelve months from the date of this filing.

Management Comments

• Management determined that the company's book value of equity exceeding its market capitalization represented an indicator of impairment with respect to its long-lived assets.
• Management concluded that the long-lived asset groups are fully recoverable and no adjustment to their carrying values was required as of September 30, 2024.
• Management believes that the revised remaining estimated useful life of the INDOCIN product rights intangible assets better reflects the realization of the economic benefit of the intangible asset.

Industry Context

The pharmaceutical industry is facing increasing pricing pressures and generic competition, which is impacting Assertio's legacy products. The company's focus on ROLVEDON, a novel oncology product, reflects a strategic shift towards higher-growth areas. The company is also navigating a complex legal landscape, which is common in the pharmaceutical sector.

Comparison to Industry Standards

• The decline in INDOCIN sales due to generic competition is consistent with industry trends where branded drugs face significant revenue erosion upon generic entry. Companies like Teva Pharmaceuticals and Mylan (now Viatris) are known for their generic drug portfolios that compete with branded products.
• The growth in ROLVEDON sales is a positive sign, but its long-term success will depend on its ability to compete with other G-CSF products from companies like Amgen (Neulasta) and Sandoz (Zarxio).
• The company's legal challenges, particularly the opioid-related litigation, are similar to those faced by other pharmaceutical companies that have marketed opioid products, such as Purdue Pharma and Johnson & Johnson.
• The company's financial performance is being compared to other small to mid-sized pharmaceutical companies that are navigating similar challenges, such as declining sales of legacy products and the need to invest in new growth drivers.

Legal Proceedings

• The company is involved in various lawsuits, claims, investigations and other legal proceedings that arise in the ordinary course of business.
• The company is involved in antitrust litigation related to its former drug Glumetza.
• The company has received and responded to subpoenas from the U.S. Department of Justice (DOJ) and various state attorneys general regarding its historical sales and marketing of opioid products.
• The company is involved in multidistrict and other federal opioid litigation.
• The company is involved in state opioid litigation.
• The company is involved in a qui tam lawsuit filed against Depomed.
• The company is involved in insurance litigation.
• The company is involved in stockholder actions, including class action lawsuits and derivative litigation.

Stakeholder Impact

• Shareholders are impacted by the decrease in revenue and the ongoing legal challenges.
• Employees may be impacted by the company's reorganization plan and cost-cutting measures.
• Customers may be impacted by changes in product availability and pricing.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• The company will continue to focus on the commercialization of ROLVEDON and manage its cost structure.
• The company will continue to defend itself in ongoing legal proceedings.
• The company will monitor the impact of generic competition on its legacy products.
• The company will continue to evaluate its operations to identify opportunities to streamline operations and optimize operating efficiencies.

Key Dates

Keywords

ROLVEDON, INDOCIN, generic competition, pharmaceuticals, revenue, net loss, acquisition, Spectrum Pharmaceuticals, litigation, convertible notes